FORMULATION OF RECOMBINANT HUMAN LUNG SURFACTANT

拟议研究的目标是制定有效的 用于治疗婴儿呼吸道疾病合成表面活性剂 窘迫综合征（RDS）。 呼吸窘迫综合征是由于 肺表面活性物质，目前通过协助 新生儿机械呼吸，治疗只有在 数量有限的医疗中心， 损害肺部。 天然肺表面活性物质治疗呼吸窘迫综合征 似乎有效，但受到人力资源稀缺的严格限制。 表面活性剂蛋白质，除了磷脂， 表面活性剂组分。 重组DNA的应用 分离和表达人类基因的技术 表面活性蛋白质应该提供无限量的 用重组蛋白配制的合成表面活性剂， 纯磷脂 两种主要的表面活性蛋白之一 （SP28-36）已被克隆，并通过重组表达 DNA方法。 我们在此提出分离并表达该基因 剩下的人类表面活性蛋白SP17

The objective of the proposed research is formulation of effective synthetic surfactant to be used in treatment of infant Respiratory Distress Syndrome (RDS). RDS is caused by inadequate levels of lung surfactant at birth, and is presently treated by assisting the newborn with mechanical respiration, a therapy available only at a limited number of medical centers, and one which can severely damage the lungs. Treatment of RDS using natural lung surfactant supplemets appears effective, but is strictly limited by the scarcity of human surfactant proteins, which in addition to phospholipids, are key components of surfactant. The application of recombinant DNA techniques to isolate and express the genes for the human surfactant proteins should provide unlimited quantities of synthetic surfactant formulated with recombinant proteins and pure phospholipids. One of the two major surfactant proteins (SP28-36) has already been cloned and expressed by recombinant DNA methods. We here propose to isolate and express the gene for the remaining human surfactant protein, SP17.